pharmaphorum

AUGUST 25, 2022

The double-headed antibody binds to CD3 on T cells and redirects them to BCMA-expressing myeloma cells, with the aim of stimulating an immune attack on the tumour, which remains incurable despite a slew of new therapies reaching the market in recent years.

FDA 98

FDA Immunization 98

pharmaphorum

APRIL 5, 2022

Immunocore now has approval on both side of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – after getting a green light from the European Commission. It’s the first treatment for mUM in the EU, as well as the first BiTE drug to treat a solid tumour.

Labelling 52

Labelling Chemotherapy Immunization 52

pharmaphorum

JANUARY 18, 2022

Two Spanish pharma companies are joining forces to identify new oral treatments for immune-inflammatory skin diseases with high unmet medical needs. Researchers at Almirall have identified several proteins whose abnormal function is associated with inflammatory immune skin diseases.

Immunization 52

Immunization 52

Pharmaceutical Technology

DECEMBER 5, 2022

CB1 receptors are primarily expressed in the brain and central nervous system, whereas CB2 receptors are expressed in T-cells in the immune system. Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total.

Controlled Substances 98

Controlled Substances Compounding Immunization 98

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. CellCentric, a U.K-based

Immunization 52

Immunization Hospitals Vaccines 52

pharmaphorum

FEBRUARY 22, 2021

Last week, Bluebird said it was pausing its Zynteglo (betibeglogene autotemcel) programme in Europe after a phase 1/2 trial in patients with sickle cell disease (SCD) – another red blood cell disorder – turned up two cases of blood cancers, one of acute myeloid leukaemia (AML) and another of myelodysplastic syndrome (MDS).

Immunization 52

Immunization 52

pharmaphorum

JANUARY 5, 2021

Like PD-L1, TIGIT is thought to act as a molecular brake that stops T cells from attacking tumours, and tiragolumab is currently leading the pack among drugs targeting the immune checkpoint. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Chemotherapy 52

Chemotherapy Immunization FDA Labelling 52

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. Currently, all approved CAR-T therapies are autologous, where T cells taken from patients are modified and then re-infused. AZ: Cell and gene therapies often come with a high price.

FDA 59

FDA Immunization 59

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Hoffmann-La Roche is the leading patent filer in the peptide nano-particle conjugates space.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunization Vaccines 52

pharmaphorum

MARCH 27, 2022

While drugs like Blenrep and teclistamab need to be administered intermittently, CAR-Ts are complex, “one and done” therapies made from a patient’s own immune cells, with a hefty price tag to match.

Labelling 91

Labelling Immunization FDA 91

The Checkup by Singlecare

JANUARY 19, 2023

DKA occurs when the body isn’t moving sugar into the cells, so it starts to burn fat for energy. Insulin helps move blood sugar to the cells, where it can be used for energy. There may also be skin tags in these areas. Diabetes People with diabetes have a fasting blood sugar of 126 mg/dl or more.

Immunization 105

Immunization Hospitals Communication 105

European Pharmaceutical Review

DECEMBER 27, 2023

Chimeric antigen receptor (CAR) T cells are the first example of a “living drug”. 1 Following in vitro production from T cells collected from a patient’s leukapheresis procedure, the CAR T cells are infused back into the patient’s blood, where they proliferate and expand. This is variable and to some extent unpredictable.

Adverse Reactions 83

Adverse Reactions Immunization Medical Schools Chemotherapy 83